Elmankabadi, B., Lee, Y., Li, Y., Guarino, A., Miller, W., Boudreau, M., Chien, B., Peterson, C. (2025). Global, phase 3, open-label, single arm studies to evaluate the efficacy, safety, and pharmacokinetics of FP-014, 11.25 mg (triptorelin mesylate injection, 11.25 mg) and FP-014, 22.5 mg (triptorelin mesylate injection, 22.5 mg) in patients with advanced prostate cancer.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.5_suppl.tps284